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ABSTRACT  25 
Background: Iron repletion augments exercise capacity in chronic heart failure (CHF) but there is a 26 
lack of mechanistic data explaining how iron could increment exercise performance despite minimal 27 
changes in hemoglobin (Hb). Besides Hb, iron is an obligate component of mitochondrial enzymes that 28 
generate cellular energy in the form of adenosine triphosphate and phosphocreatine (PCr). Dynamic 29 
phosphorus magnetic resonance spectroscopy (31P MRS) is a noninvasive tool that quantifies in vivo 30 
muscle energetics by measuring the kinetics of PCr recovery after exertion. We tested the hypothesis 31 
that intravenous (IV) iron repletion in CHF enhances skeletal muscle energetics as reflected by shorter 32 
PCr recovery half-times (PCr t1/2) on 31P MRS.  33 
 34 
Methods: We enrolled 40 patients (50% anemic) with CHF, NYHA class≥ II, LVEF≤ 45%, and iron 35 
deficiency (ferritin<100µg/L or 100-300µg/L with transferrin saturation [TSAT]< 20%). Subjects 36 
underwent stratified (anemic vs non-anemic) randomization (1:1) to a single, double-blinded, total dose 37 
infusion of Iron Isomaltoside (IIM) or saline placebo with endpoints reassessed early at 2 weeks post-38 
treatment to minimise confounding from exercise adaptation. The primary endpoint was PCr t1/2 at 2 39 
weeks. Secondary endpoints included adenosine diphosphate recovery half-time (ADP t1/2; energetic 40 
marker), iron status, symptoms, Hb, exercise capacity and safety. 41 
 42 
Results: In the total population, treatment groups were similar at baseline. At 2 weeks, IIM improved 43 
PCr t1/2 (adjusted difference -6.8s [95% confidence interval 11.5,-2.1], P=0.006), ADP t1/2 (-5.3s [-9.7,-44 
0.9], P=0.02), ferritin (304ng/mL [217,391], P<0.0001), TSAT (6.8% [2.7,10.8], P=0.002), NYHA 45 
class (-0.23[-0.46,-0.01], P=0.04), resting respiratory rate (-0.7 breaths/min [-1.2,-0.2], P=0.009) and 46 
post-exercise Borg dyspnea score (-2.0[-3.7,-0.3], P=0.04), but not Hb (2.4g/L [-3.5,8.4], P=0.41). 47 
Adverse events were similar between groups. In subgroup analyses, IIM improved PCr t1/2 in anemic (-48 
8.4s [-16.7,-0.2], P=0.04) and non-anemic (-5.2s [-10.6,0.2], P=0.06) cohorts. 49 
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Conclusion: In patients with CHF and ID, a total repletion dose of IIM given at a single sitting is well 50 
tolerated and associated with faster skeletal muscle PCr t1/2 at 2 weeks, implying better mitochondrial 51 
function. Augmented skeletal muscle energetics might therefore be an important mechanism via which 52 
iron repletion confers benefits in CHF despite minimal Hb changes. 53 
 54 
Clinical Trial Registration: URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-005592-55 
13/GB. Unique identifier: EudraCT 2012-005592-13. 56 
57 
FERRIC HF II  
     4 
CLINICAL PERSPECTIVE 58 
What is New? 59 
• Little is known about how intravenous iron repletion augments exercise capacity in chronic 60 
heart failure (CHF) despite minimal hemoglobin changes.  61 
• This randomized, double-blind, placebo-controlled Ferric Iron in Heart Failure (FERRIC-HF) II 62 
trial shows that a single total dose infusion of Iron Isomaltoside repleted iron stores and 63 
augmented skeletal muscle energetics at 2 weeks post-infusion. 64 
• Enhancements in skeletal muscle energetics, which imply better mitochondrial function, were 65 
accompanied by improved symptoms despite no change in hemogobin at 2 weeks. 66 
 67 
What are the Clinical Implications? 68 
• Augmented skeletal muscle energetics is a likely mechanism via which iron repletion confers 69 
benefits in CHF despite minimal hemoglobin changes.  70 
• FERRIC-HF II supports clinical iron repletion in CHF. 71 
• A total repletion dose of Iron Isomaltoside given at a single sitting is feasible in CHF patients. 72 
73 
FERRIC HF II  
     5 
INTRODUCTION 74 
Iron deficiency (ID) is prevalent and ominous in chronic heart failure (CHF),1-4 and its correction 75 
markedly improves symptoms and exercise tolerance. Yet, in landmark studies such as the seminal 76 
FERRIC-HF (Ferric Iron in Heart Failure) trial, the hemoglobin (Hb) response to intravenous (IV) iron 77 
was surprisingly small (5 g/L increase over 4 months),3,4 and did not correlate with changes in exercise 78 
indices. Consequently, it is unknown how IV iron augments exercise capacity despite minimal changes 79 
in Hb, and this paucity of mechanistic data partly hampers the clinical uptake of iron repletion in CHF. 80 
 81 
Exercise is a highly energetic process with skeletal muscle contractions powered by the hydrolysis of 82 
adenosine triphosphate (ATP) which is buffered by phosphocreatine (PCr) consumption.5,6 To sustain 83 
exertion, PCr is resynthesised via glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) 84 
which generates over 95% of cellular ATP.7,8 Iron is a component of Hb and myoglobin, and of 85 
proteins of the Krebs cycle, ß-oxidation pathway, and the electron transport chain which determine 86 
OXPHOS capacity.9-12 In animal studies, cellular ID triggers mitochondrial dysfunction and exercise 87 
intolerance, even in the absence of anemia.13-15 Thus, iron repletion might enhance exercise capacity by 88 
energizing skeletal muscle independently of Hb. To date, no clinical trial has addressed this in humans. 89 
 90 
Dynamic phosphorus magnetic resonance spectroscopy (31P MRS) is uniquely suited to quantifying 91 
human skeletal muscle energetics in vivo.16,17 It enables the real-time noninvasive tracking of skeletal 92 
muscle PCr, ATP and inorganic phosphate (Pi) concentrations and cytostolic pH during exercise and 93 
recovery. Because PCr replenishment on cessation of exercise is predominantly driven  by OXPHOS,18 94 
the PCr recovery half-time (PCr t1/2) is an inverse marker of mitochondrial oxidative function that is 95 
relatively independent of exercise intensity.16 We conducted the FERRIC-HF II trial to test the 96 
hypothesis that iron repletion with a single total dose infusion of Iron Isomaltoside (IIM) would 97 
improve skeletal muscle energetics as reflected by a shorter PCr t1/2 in CHF patients. 98 
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METHODS 99 
Study Design 100 
FERRIC-HF II was an investigator-led, randomized, double-blind, placebo-controlled, mechanistic trial 101 
conducted at King's College Hospital, London, UK. The study involved 1 screening visit, 2 baseline 102 
visits within 4 weeks of screening, and 2 final visits 2 weeks after treatment allocation. The protocol 103 
was approved by the South-Central Berkshire ethics committee, the UK Medicines and Healthcare 104 
products Regulatory Agency, and the independent local research governance board. King's College 105 
London University and King's College Hospital NHS Foundation Trust were co-sponsors. The King's 106 
Health Partners clinical trial office monitored the trial and ensured compliance with the International 107 
Conference on Harmonization guidelines for Good Clinical Practice and the Declaration of Helsinki. 108 
Written informed consent was obtained from all patients. The trial is registered on 109 
clinicaltrialsregister.eu (EudraCT 2012-005592-13) and data from this analysis is obtainable from the 110 
authors on reasonable request. 111 
 112 
Study Patients 113 
Eligibility criteria were: age ≥30 years; stable symptomatic CHF (New York Heart Association 114 
[NYHA] III and left ventricular ejection fraction [LVEF] ≤45%, or if NYHA II then LVEF ≤40% 115 
within the preceding 6 months); use of optimal CHF drugs for ≥4 weeks without dose changes for ≥2 116 
weeks; screening Hb <120 g/L in females and < 130 g/L in males (anemic group) or ≥120 g/L in 117 
females and  ≥ 130 g/L in males (non-anemic group); ID as defined by the FERRIC-HF criteria of 118 
ferritin <100 µg/L or 100-300 µg/L with transferrin saturation (TSAT) <20%;3 folate and vitamin B12 119 
levels ≥ lower limit of reference range; resting blood pressure ≤160/100 mm Hg; and a negative 120 
pregnancy test in women of child-bearing age. 121 
 122 
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Exclusion criteria were a history of acquired iron overload, known hemochromatosis or first degree 123 
relatives with hemochromatosis; an allergic disorder (e.g., asthma, eczema, and anaphylactic reactions); 124 
prior hypersensitivity to IV iron drugs or their excipients; active infection, bleeding, malignancy, 125 
hemolytic anemia, rheumatoid arthritis, and myelodysplasia; HIV/AIDS; chronic liver disease with 126 
transaminases >3 times the upper limit of the reference range; chronic lung disease with FEV1 < 50% 127 
predicted; coagulopathy or anticoagulated for a metallic valve or LV thrombus; contraindications to 128 
MRS; immunosuppressant use; renal dialysis; need for erythropoietin or blood transfusions; unstable 129 
angina; severe obstructive cardiac lesions; uncontrolled arrhythmias; and musculoskeletal limitations. 130 
 131 
Randomization 132 
Qualifying patients attended for 2 baseline visits at week 0 collectively including a clinical history, 133 
physical examination, NYHA class assessment, 12-lead electrocardiogram, blood tests, Kansas City 134 
Cardiomyopathy Questionnaire (KCCQ), echocardiogram, 6-min walk test, cardiopulmonary exercise 135 
test, quadriceps muscle 31P MRS, and a vastus lateralis muscle biopsy. At the end of the second visit, 136 
patients were randomly assigned within 2 strata (anemic or non-anemic) in permuted blocks of 4 to a 137 
single total repletion dose of IIM or placebo (normal saline) in a 1:1 ratio.  Randomization was 138 
performed by a clinical trials pharmacist using an automated web-based system (Sealed Envelope Ltd, 139 
London, UK). 140 
 141 
Study Drug and Blinding 142 
Iron (III) isomaltoside 1000 (Monofer®; Pharmacosmos A/S, Holbaek, Denmark) was provided as a 143 
solution for IV infusion in 100mg iron/mL ampoules. The total repletion dose was calculated to the 144 
nearest multiple of 100mg using the Ganzoni formula: body weight (kg) x 2.4 x (15 - patients 145 
Hb[g/dL]) + 500 mg (for stores).19 Doses of 0-10 mg/kg and 11-20 mg/kg were infused over 30 and 60 146 
minutes respectively. Doses exceeding 20 mg/kg were split and given at 2 separate sittings 1 week 147 
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apart. Monofer® was added to 100 mL sterile 0.9% saline for infusions. Patients randomized to placebo 148 
had their repletion dose and infusion duration calculated as above but received 100 mL sterile 0.9% 149 
saline over the infusion period. All patients were observed for 1 hour post treatment with heart rate and 150 
blood pressure documented every 15 minutes. Patients who received placebo were offered Monofer® at 151 
the end of the study if they remained iron-deficient.  152 
 153 
To achieve blinding, allocated therapy was dispensed by a clinical trials pharmacist to unblinded 154 
research nurses who prepared and administered the infusions using opaque IV bags and giving sets 155 
(Medipak, Virginia, USA). All other members of the research team vacated the infusion room before 156 
the allocated therapy was collected from pharmacy. A curtain shielded the infusion arm from the 157 
patient. The unblinded nurse was not involved in assessing endpoints.   158 
 159 
Primary Endpoint 160 
The primary endpoint was skeletal muscle energetics at 2 weeks post-treatment as assessed by the PCr 161 
t1/2 on dynamic 31P MRS. This was performed on a clinical 3T scanner (Achieva, Philips Medical 162 
Systems, Best, the Netherlands). Patients were asked to refrain from strenuous exercise and alcohol for 163 
the preceding 24 hours, and from caffeine and food for the preceding 6 and 2 hours, respectively. 164 
Heights and weights were measured to the nearest integer and used to calculate lean body mass.20 165 
Subjects were positioned feet-first and supine in the scanner and a 14 cm diameter 31P surface coil 166 
(Philips Medical Systems, Best, the Netherlands) was strapped to the dominant quadriceps. A non-167 
ferromagnetic weight, equivalent to 10% of lean body mass, was strapped to the dominant ankle 168 
(Figure 1).17 This load was chosen to target an ~30% exertional fall in PCr from baseline thereby 169 
avoiding any significant lowering of pH (<6.8) which prolongs PCr t1/2.21 Participants then practiced 170 
knee extensions before full entry into the scanner bore, where they were positioned such that the centre 171 
of the 31P coil was at magnet isocenter. A series of triplanar 1H scout images were acquired and used 172 
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for automatic shimming to optimize the B0 field homogeneity. Continuous 31P spectra were then 173 
acquired (unlocalised, repetition time 2 sec, echo time 0.35 msec, bandwidth 2000 Hz, excitation flip 174 
angle optimized for flip angle and 1024 data points) in conjunction with the exercise paradigm 175 
consisting of 1 min rest, 1 min knee extensions at 0.5 Hz, and 5 min recovery. This was repeated to 176 
permit two PCr t1/2 measurements which were then averaged. The same MRS sequence was acquired 177 
with a repetition time of 30 sec (8 averages) to provide a fully relaxed spectrum for the calculation of 178 
metabolite concentrations. 179 
 180 
31P MRS spectra were analysed using jMRUI v5.2 and quantified using the AMARES algorithm with 181 
prior knowledge.22,23 Absolute concentrations of PCr and Pi were calculated making the standard 182 
assumption that resting ATP concentration is 8.2 mmol/L cytosolic water (i.e. mM).24 Intramuscular 183 
pH was estimated from the chemical shift of Pi using the following equation: pH = 6.75 + log (α-184 
3.27/5.69-α), where α is the chemical shift of the Pi peak relative to PCr.25 Free cytosolic ADP 185 
concentration was calculated by standard means using the creatine kinase equation: ADP = ATP x 186 
creatine / [PCr x H+ x 1.66 x 109 M-1], and assuming that total creatine is 42.5 mM.24 The PCr t1/2 was 187 
found by fitting the following monoexponential equation to the PCr recovery data: PCr(t) = PCrinitial + 188 
(PCrend - PCrinitial)(1-e-kt), where t is the time from the end of exercise, PCrinitial and PCrend are the PCr 189 
concentrations at the start and end phase of recovery, and k is the recovery rate constant. PCr t1/2 is 190 
calculated as loge2/k. The analogous monoexponential equation was fitted to the ADP recovery data to 191 
determine ADP t1/2, another inverse marker of skeletal muscle energetics.16    192 
 193 
Secondary and Safety Endpoints 194 
Secondary endpoints included (1) skeletal muscle energetics as reflected by the ADP t1/2 and the 195 
intracellular concentrations of high-energy phosphate compounds and pH on dynamic 31P MRS; (2) 6-196 
min walk distance; (3) peak oxygen consumption (VO2) and the ratio of minute ventilation to CO2 197 
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production on cardiopulmonary exercise testing; (4) symptoms as quantified by the NYHA class, Borg 198 
dyspnea score, and fatigue scale (assessed using a 10-point visual analogue fatigue scale, from 1 = no 199 
fatigue, to 10 = very severe fatigue); (5) quality of life as assessed by the KCCQ; (6) Hb and iron status 200 
(ferritin, TSAT, soluble transferrin receptor); (7) N-terminal pro-B-type natriuretic peptide (NT-201 
proBNP); and (8) LVEF. 202 
 203 
The 6-min walk test was performed using a flat, straight, 20-m corridor with turnaround points marked 204 
by a chair at each end of the measured course. Patients were verbally encouraged to cover as much 205 
ground at their own pace for 6 min and were asked to rate themselves on a Borg dyspnea scale before 206 
and after exercising. The same blinded investigator supervised all 6-min walk tests for a specific 207 
subject. Cardiopulmonary exercise testing was performed using a modified Naughton treadmill 208 
protocol.26 Maximal exercise capacity was attained if the respiratory exchange ratio was >1.00 or had 209 
increased by ≥0.15 from the resting value. All treadmill exercise tests were supervised by blinded 210 
cardiac physiologists.  211 
 212 
Safety endpoints included (1) adverse events; (2) blood pressure; (3) heart rate; (4) respiratory rate; (5) 213 
serum creatinine concentration; (6) serum AST; (7) serum C-reactive protein; and (8) blood pressure 214 
and heart rate during treatment infusions.  215 
 216 
Statistics 217 
Statistical analyses were prespecified and followed the intention-to-treat principle.  Sample size 218 
estimates were hampered by a paucity of quadriceps 31P MRS data in patients with CHF. Initial 219 
calculations based on a trial using calf 31P MRS,27 suggested that 40 patients in total would be needed 220 
to detect a 30 sec difference in PCr t1/2 (α = 0.05, β = 90%, standard deviation = 24 sec) and cover for 221 
drop-outs and missing data. Review of the accruing blinded data suggested that the variance and 222 
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standard deviation of PCr t1/2 were likely to be smaller but that 40 patients in total was still sufficient to 223 
detect a more conservative difference of 6 sec with a standard deviation of 5 sec (α = 0.05, β = 90%).  224 
 225 
The primary analysis was a comparison of PCr t1/2 at 2 weeks using an analysis of covariance model 226 
with baseline PCr t1/2 as covariate. All other continuous endpoints were similarly analysed. Missing 227 
data were imputed using the last observation carry-forward method for patients who had a last 228 
observation recorded post treatment. For those who did not, the mean value for their treatment group 229 
was used for imputations. Sensitivity analyses without imputation and with a post-hoc Markov chain-230 
Monte Carlo imputation with 10 iterations were performed. Categorical variables were evaluated using 231 
a Pearson’s χ2 test. Baseline and week-2 data are described using appropriate summary measures. The 232 
estimates and two-sided 95% confidence intervals (95% CI) for the difference between least-squares 233 
means of the two treatment arms are given. All statistical tests were two-sided and we judged a P-value 234 
< 0.05 significant. All analyses were carried out using Stata 9.2 (Statacorp, Texas) and Statview 4.5 for 235 
Windows (Abacus Concepts, California). 236 
237 
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RESULTS 238 
Patients and Iron Isomaltoside Administration 239 
Between October 2014 and December 2016, we screened 83 outpatients (Figure 2) and randomized 40 240 
to IIM (n=21) or placebo (n=19). Baseline characteristics were balanced between the two treatment 241 
groups (Table 1). All patients received their allocated therapy at a single sitting except for 1 subject 242 
who received placebo over 2 sittings. In those randomized to IIM, the mean iron repletion dose was 243 
929±320 mg (11±4 mg/kg). No subject was lost to follow-up and only 1 patient did not attend an end-244 
of-study visit due to hospitalization. Overall, 4.2% of the analysed data was imputed.  Sensitivity 245 
analyses yielded consistent results.  246 
 247 
Primary Endpoint 248 
During dynamic 31P MRS the treatment arms exercised against similar weights (IIM: 5.7±0.7 kg, 249 
placebo: 5.5±0.9 kg, P=0.57) and achieved similar degrees of exertional PCr depletion at baseline (IIM: 250 
36±11%, placebo: 34±13%, P=0.52) and at 2 weeks (IIM: 38±13%, placebo: 37±9%, P=0.71). At 251 
baseline, post-exercise PCr t1/2 was similar in the randomized groups (Table 1). After treatment, PCr t1/2 252 
improved (shortened) by 17% (-4±10 sec) in the IIM group and worsened by 7% (3±7 sec) in the 253 
placebo arm (Table 2). The primary endpoint, PCr t1/2 at 2 weeks, was significantly shorter in patients 254 
randomized to IIM with an adjusted between-group difference of – 6.8 sec (95% CI -11.5 to -2.1, 255 
P=0.006; Table 2, Figure 3). This remained significant even after post-hoc adjustment for both baseline 256 
PCr t1/2 and Hb (-6.8 sec, 95% CI -11.6 to -2.0, P=0.007) or other variables that appeared unbalanced 257 
such as age (-8.0 sec, 95% CI -12.8 to -3.2, P=0.002),  and NTpro-BNP (-7.2 sec, 95% CI-10.5 to -1.0, 258 
P=0.007). No anemia status by treatment group interaction existed (P=0.44). 259 
 260 
Secondary Endpoints  261 
Skeletal Muscle ADP t1/2, Metabolite Concentrations and pH 262 
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Treatment with IIM significantly improved (shortened) post-exercise ADP t1/2 (Table 2) by 45% (-5±9 263 
sec) while it lengthened by 3% (3±7 sec) with placebo. No difference in resting or end-exercise PCr 264 
and ADP levels were seen between the groups after treatment (Table 2). Neither the resting nor end-265 
exercise pH differed between the groups after treatment (Table 1 & 2), and only 1 patient at baseline, 266 
and no patient at 2 weeks, had a pH ≤ 6.8 during exercise. Possibly due to this limited acidosis, no 267 
correlation was seen between exertional pH decrements and the degree of PCr depletion, iron status or 268 
the visual analogue fatigue scale. As expected, changes in ADP t1/2 correlated with changes in PCr t1/2 269 
(r=0.65, P<0.001). 270 
 271 
Hemoglobin and Iron Status 272 
Ferritin increased by 83% (327±185 ng/mL) in the IIM group and decreased by 24% (2±27 ng/mL) in 273 
the placebo group (Table 2). Similarly, TSAT increased by 29% (8±6%) with IIM and by 4% (2±9%) 274 
with placebo. Despite this, Hb remained largely unchanged, being minimally increased by 0.4% (0.6±9 275 
g/L) in the IIM arm, and minimally decreased by 0.8% (-1±14 g/L) in the placebo arm. Changes in 276 
ferritin (log transformed; r= -0.37, P=0.02) but not Hb (r=0.17, P=0.30) correlated with changes in PCr 277 
t1/2. 278 
 279 
Symptoms, Exercise Capacity, LVEF and NT-proBNP 280 
Therapy with IIM improved symptoms as reflected by reductions in NYHA class and the post-exercise 281 
Borg dyspnea score (Table 2). After 2 weeks, 2 (10%), 19 (90%), and 0 (0%) patients in the IIM group 282 
had an improved, unchanged, or worse NYHA class, respectively. By contrast, 1 (5%), 15 (79%), and 3 283 
(16%) patients in the placebo group had an improved, unchanged, or worse NYHA class. There was no 284 
difference in the pre-exercise Borg dyspnea score (-0.6, 95% CI -1.5 to 0.2, P=0.12), visual analogue 285 
fatigue scale or the KCCQ score (Table 1). Symptomatic improvements were not accompanied by 286 
significant changes in LVEF, NT-proBNP, 6-min walk distance, visual analogue fatigue scale (-0.59, 287 
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95% CI -1.45 to 0.28, P=0.18), peak VO2 or the ratio of minute ventilation to CO2 production (-0.2, 288 
95% CI -3.3 to 2.9, P=0.88) despite both groups attaining similar peak respiratory exchange ratios at 289 
baseline (Table 1) and at week 2 (IIM: 1.10±0.10, placebo: 1.05±0.09). Changes in 6-min walk 290 
distance related to changes in PCr t1/2 (r= -0.33, P=0.04), and peak VO2 related to PCr t1/2 in the IIM 291 
(r=-0.57, P=0.007) but not placebo (r=-0.30, P=0.21) group at 2 weeks. 292 
 293 
Safety Endpoints  294 
The incidence of adverse events was comparable between the treatment arms with 3 (14%) and 1 (5%) 295 
events in the IIM and placebo groups, respectively (P=0.34). In the IIM arm, 1 patient had arthralgia 296 
during the infusion, 1 patient noted a mild rash at the venepuncture site 1 day post-infusion, and 1 297 
patient had a serious adverse event (hospitalized 1 week post-infusion with unstable angina needing 298 
coronary artery bypass surgery) that was judged unrelated to study drug. No anaphylactic reactions 299 
occurred. In the placebo arm, 1 patient reported coryzal symptoms 3 days post-infusion. 300 
 301 
Infusions of IIM had no impact on hemodynamics. Systolic blood pressure remained unchanged from 302 
pre-infusion (122±17 mmHg) to 15 (123±17 mmHg), 30 (122±17 mmHg), 45 (119±19 mmHg), and 60 303 
(121±15 mmHg) minutes post-infusion (all P>0.05). Diastolic blood pressure and heart rate were 304 
similarly stable. At 2 weeks, no differences between the treatment arms were seen for blood pressure, 305 
heart rate, and serum creatinine, AST or CRP levels, but IIM was associated with significantly reduced 306 
respiratory rates (Table 2).  307 
 308 
Subgroup Analysis  309 
Baseline characteristics for the anemic and non-anemic subgroups stratified by treatment allocation are 310 
shown in Table 1. Mean iron repletion dose was 1155±221 mg (13±2 mg/kg) in anemic patients and 311 
680±204 mg (9±3 mg/kg) in non-anemic patients. Baseline PCr t1/2 was similar in the randomized 312 
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groups in both anemic and non-anemic subpopulations. Infusion of IIM significantly improved 313 
(shortened) PCr t1/2 at 2 weeks in anemic patients. A smaller improvement in non-anemic subjects did 314 
not reach statistical significance (Table 3).  315 
  316 
317 
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DISCUSSSION 318 
FERRIC-HF II sought to illuminate how iron repletion could dramatically augment exercise 319 
performance in CHF despite minimal Hb changes. We found that, in iron-deficient patients with CHF 320 
and an LVEF ≤45%, a single total dose infusion of IIM safely repleted iron stores and was associated 321 
with faster skeletal muscle post-exercise PCr recovery kinetics at 2 weeks, implying better 322 
mitochondrial function. Enhancements in skeletal muscle energetics occurred despite no change in Hb, 323 
but were paralleled by improvements in symptoms as reflected by reductions in NYHA class and the 324 
post-exercise Borg dyspnea score. Augmented skeletal muscle energetics might therefore be an 325 
important mechanism via which iron repletion improves functional capacity despite eliciting minimal 326 
Hb changes.  327 
 328 
Dynamic 31P MRS is uniquely able to quantify in vivo skeletal muscle energetics non-invasively. At 329 
rest, skeletal muscle pH and phosphometabolite (PCr, Pi, ADP) concentrations are dictated not by ATP 330 
supply and demand but by sarcolemmal Na+-dependent Pi and creatine uptake, Na+/H+-antiporter 331 
activity, and the net balance of adenine nucleotide breakdown and synthesis.16 At the onset of exercise, 332 
ATP consumption by myosin-ATPases increases ATP demand which is met immediately by local PCr 333 
breakdown via the creatinine kinase reaction to regenerate ATP.7 Sustained exertion is then driven by 334 
mitochondrial PCr regeneration via OXPHOS and glycolysis.5-8 Therefore, during exertion, ATP levels 335 
remain largely unchanged due to rapid PCr buffering, PCr declines due to its heightened consumption, 336 
pH falls due to elevated glycolysis, and ADP and Pi rise due to increased ATP hydrolysis and PCr 337 
consumption. At the end of exercise, PCr consumption and glycolysis cease and PCr levels start to 338 
recover at a rate commensurate with mitochondrial oxidative ATP synthesis.24 Dynamic 31P MRS 339 
enables the real-time noninvasive tracking of these biochemical events in situ, with 31P MRS measures 340 
closely related to peak VO2 and invasive markers of muscle energetics.16,28,29 In our cohort, resting pH 341 
and phosphometabolite concentrations mirrored those reported in other CHF patients and normal 342 
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subjects30-32 and were unaltered by IIM. This implies that the processes dictating resting skeletal 343 
muscle indices were unperturbed in our subjects and were not influenced by IIM over 2 weeks. On 344 
initiation of mild to moderate exercise in-magnet, skeletal muscle ATP levels remained constant, PCr 345 
and pH fell, and ADP and Pi rose in our patients as expected (see Figure 2). That the degree of 346 
exertional PCr depletion was similar in the treatment groups implies comparable effort. That only 1 347 
patient developed significant intracellular acidosis (exercise pH <6.8), which slows PCr t1/2,21 implies 348 
that our exercise paradigm did not evoke significant glycolysis and that our PCr t1/2 values likely truly 349 
reflected oxidative ATP synthesis capacity.  350 
 351 
To the best of our knowledge, this is the first study to show that iron repletion with IIM augments 352 
skeletal muscle energetics as reflected by a 14% relative acceleration of PCr recovery kinetics on 353 
dynamic 31P MRS. This represents a substantial benefit. In a randomized trial in CHF patients, 354 
Adamapolous et al., reported a 5% weekly rate of improvement in PCr t1/2 with moderate-intensity 355 
exercise training.33 In a double-blind evaluation of the energetic enhancer perhexiline, Lee et al., 356 
documented a 4% weekly rate of improvement in PCr t1/2 in CHF patients.27 In young healthy 357 
individuals, 2 weeks of high-intensity exercise training improved PCr recovery by 14% with no change 358 
in the untrained control group.34 Thus, over 2 weeks, a single total repletion dose of IIM augmented 359 
skeletal muscle energetics to the same extent as 3 weeks of moderate-intensity exercise training in 360 
CHF, 3-4 weeks of perhexiline use in CHF, and 2 weeks of high-intensity physical training in younger 361 
healthy individuals. In contrast, Melenovsky et al., very recently found no difference in PCr recovery 362 
kinetics 4 weeks after infusing Ferric Carboxymaltose (1g) in 13 CHF patients.35 This might be because 363 
their patients exercised longer (6 mins vs. 1 min) against higher resistance (7kg vs. 5.6±0.8kg) during 364 
31P MRS, leading to greater intracellular acidosis (pH 6.92±0.17 vs 6.98±0.07) which renders PCr 365 
recovery kinetics less informative of OXPHOS.16,18,21 This might also reflect their smaller sample size, 366 
lack of randomization and a control group, later reassessment at 4 weeks, or the use of Ferric 367 
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Carboxymaltose which uniquely induces hypophosphatemia which could blunt energetic gains from 368 
iron repletion.36-38 Several explanations for our findings can be posited.  369 
 370 
Post-exercise PCr t1/2 is influenced by skeletal muscle O2 supply (determined by cardiopulmonary 371 
function and Hb), storage (myoglobin), and utilization (mitochondria),16 which are all modifiable by 372 
iron. While we had no pulmonary data, cardiac function and hemodynamics were unaltered by IIM 373 
consistent with evidence that O2 delivery does not limit post-exercise PCr recovery in CHF.39 Skeletal 374 
muscle myoglobin levels are also reportedly normal and exertional myoglobin desaturation in CHF 375 
does not restrict skeletal muscle metabolism.40,41 So, the benefits of IIM are unlikely mediated via O2 376 
storage. A key mechanistic finding in FERRIC-HF II was our observation that Hb levels did not change 377 
with IIM. This accords with data in CHF showing that ID impairs exercise tolerance independently of 378 
Hb,1,2 that iron repletion improves functional capacity despite minimal Hb changes,3,4 and that such Hb 379 
changes do not correlate with increments in exercise performance.3,4 Although skeletal muscle benefits 380 
were greater in our anemic subgroup, this is probably not a function of lower Hb per se but may reflect 381 
the fact that anemic patients had a poorer iron status than non-anaemics. Thus, IIM likely improved 382 
energetics by altering skeletal muscle O2 utilization.  383 
 384 
Mitochondria power cellular processes and mitochondrial dysfunction due to ID might have been 385 
mitigated by IIM via numerous mechanisms. This includes acceleration of the electron transport chain 386 
which sets the pace for OXPHOS and contains iron-sulfur cluster and heme prosthetic groups.8,12 Iron 387 
is also embedded in enzymes of the Krebs cycle,fatty acid ß-oxidation, and carnitine synthesis,42 and is 388 
active in catalase which maintains a permissive redox environment for efficient OXPHOS activity.43 In 389 
human CHF, myocardial ID is linked to diminished catalase and Krebs cycle enzyme levels.44 In in 390 
vitro and animal studies, cellular ID impairs cardiomyocyte and skeletal muscle energetics even in the 391 
absence of anemia.13,14,45 Indeed, in rats with ID anemia, correction of anemia but not ID failed to 392 
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improve submaximal exercise capacity (which is determined by oxidative enzymes).15 In contrast, 393 
correction of ID but not anemia improved submaximal exercise performance within 15 hours of iron 394 
infusions.46  395 
 396 
Besides skeletal muscle energetic augmentation by IIM, several other aspects of our study bear special 397 
emphasis. First, symptoms were improved by IIM at 2 weeks, with reductions in NYHA class and Borg 398 
score corroborated by attenuations in resting respiratory rate (presumably due to improved respiratory 399 
muscle energetics). Apart from diuretics, no other contemporary CHF therapy can likely match this 400 
pace of symptomatic benefit. Second, this is the first trial to test the utility of infusing a total repletion 401 
dose of iron at a single sitting. By 2 weeks, we achieved the same degree of biochemical iron repletion 402 
as was achieved by 6 to 12 months in prior studies.4 Third, FERRIC-HF II is the first to show, in a 403 
double-blind placebo-controlled trial, that IIM ameliorates ID in CHF patients.  404 
 405 
Our study has limitations. We were underpowered to detect differences in certain clinical indices (e.g., 406 
peak VO2 and 6-min walk distance), in safety endpoints such as rare side-effects of IIM, and in the 407 
anemic and non-anemic subgroups. This might explain some of our modest correlations and the near-408 
significant effect of IIM on PCr t1/2 in non-anemics which merits further study. We did not measure 409 
skeletal muscle blood flow so cannot exclude improved limb perfusion as a contributor to enhanced 410 
muscle energetics. However, blood supply does not limit skeletal muscle metabolism in CHF,39 so it is 411 
unlikely that any theoretical increase in perfusion with IIM could influence PCr t1/2. We chose a short 412 
trial duration to minimize attribution of results to skeletal muscle exercise adaptation, so the energizing 413 
effect of IIM might have been greater with a longer trial. No adjustments were made for multiple 414 
comparisons and we used the last observation carry forward method for imputations.  415 
 416 
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FERRIC-HF II has potentially important clinical ramifications. Despite data that ID is common and 417 
adverse in CHF,1,2 and that its correction confers benefits,3,4 clinical uptake of routine iron repletion, 418 
particularly in non-anemic patients, remains poor. One potential barrier to adoption is the lack of 419 
mechanistic data explaining how iron could trigger such profound exercise benefits despite minimal 420 
changes in Hb. Our findings should therefore go some way to reassure clinicians that the benefits of IV 421 
iron are real and appear to have a sound mechanistic underpinning. Second, our data reinforces the 422 
importance of routinely checking iron indices in CHF patients, and emphasizes that the treatment target 423 
should be iron status and not necessarily Hb. Third, our study suggests that a single total repletion dose 424 
of IIM can safely replete iron stores with clinical benefits.   425 
 426 
In conclusion, the FERRIC-HF II trial has shown that, in patients with CHF and ID, a total repletion 427 
dose of IIM given at a single sitting is well tolerated and associated with faster skeletal muscle post-428 
exercise PCr recovery kinetics at 2 weeks, implying better mitochondrial function. Enhanced skeletal 429 
muscle energetics occurs despite no change in Hb, but is accompanied by improved symptoms. 430 
Augmented skeletal muscle energetics might therefore be an important mechanism via which iron 431 
repletion improves exercise capacity in CHF despite minimal changes in Hb. 432 
433 
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	  All patients  Anemic patients  Nonanemic patients 
  
Placebo  
(n=19)   
Iron Isomaltoside  
(n=21)   
 Placebo 
(n=9) 
Iron Isomaltoside  
(n=11) 
 Placebo 
(n=10) 
Iron Isomaltoside  
(n=10) 
Demographics         
 Age, years 62±13 70±12  63±15 74±6  61±11 65±15 
 Male gender, n (%) 13(68) 16(76)  7(78) 11(100)  6(60) 5(50) 
 Caucasian ethnicity, n (%) 14(74) 17(81)  6(67) 10(91)  8(80) 7(70) 
 Body mass index, kg/m2 30±7 29±4  29±6 29±4  30±8 29±5 
 Ischemic etiology, n (%) 10(53) 11(52)  6(67) 7(64)  4(40) 4(40) 
Comorbidities         
 Coronary artery disease 11(58) 13(62)  6(67) 9(82)  5(50) 4(40) 
 Hypertension 13(64) 13(62)  5(56) 8(73)  8(80) 5(50) 
 Hyperlipidemia 7(37) 7(33)  2(22) 6(55)  5(50) 1(10) 
 Diabetes mellitus 10(53) 10(48)  6(67) 7(64)  4(40) 3(30) 
 Atrial fibrillation/flutter 4(21) 6(29)  2(22) 3(27)  2(20) 3(30) 
Clinical and quality of life         
 LV ejection fraction, % 37±8 37±8  37±8 36±9  37±7 39±7 
 NYHA class 2.4±0.5 2.5±0.5  2.5±0.5 2.4±0.5  2.5±0.5 2.4±0.5 
 NYHA class III, n (%) 10(53) 9(43)  4(44) 6(55)  6(60) 3(30) 
 Systolic BP, mm Hg 122±17 124±16  115±14 125±14  128±17 124±18 
 Diastolic BP, mm Hg 71±14 73±10  67±11 71±8  75±16 76±12 
 Heart rate, beats/min 71±11 72±10  67±6 71±6  74±13 72±13 
 Respiratory rate, breaths/min 16±1 16±1  16±1 16±1  16±1 15±1 
 KCCQ overall score 53±20 64±23  58±27 66±19  48±13 62±28 
Exercise parameters         
 Peak VO2, mL/kg/min 14.3±3.1 15.8±4.3  12.7±3.2 16.0±5.6  15.8±2.2 15.6±2.5 
 Peak respiratory exchange ratio 1.06±0.11 1.10±0.10  1.05±0.10 1.14±0.10  1.07±0.12 1.07±0.10 
 CPET exercise duration, s  582±202 627±241  551±252 636±289  610±153 617±191 
 6 min walking distance, m 313±67 324±79  295±70 299±84  330±64 351±68 
 Pre-exercise Borg dyspnea score 11±1 11±1  11±1 11±2  11±1 11±1 
 Post-exercise Borg dyspnea score 15±2 14±3  15±2 15±3  14±2 14±2 
Table 1. Baseline characteristics. Data are mean±SD, numbers(%), or median (interquartile range).  
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  All patients  Anemic patients  Nonanemic patients 
  
Placebo  
(n=19)   
Iron Isomaltoside  
(n=21)   
 Placebo  
(n=9) 
Iron Isomaltoside  
(n=11) 
 Placebo  
(n=10) 
Iron Isomaltoside  
(n=10) 
31P MRS measurements         
 Resting PCr, mM 39±4 40±6  39±4 42±7  40±5 38±5 
 Exercise PCr, mM  26±4 25±6  23±5 25±7  28±3 25±5 
 Resting Pi, mM 4.3±1.0 4.0±0.7  4.4±1.0 3.9±0.8  4.1±1.1 4.2±0.6 
 Exercise Pi, mM 18.3±6.8 19.1±7.2  18.8±6.9 20.7±8.8  17.9±7.1 17.3±4.8 
 Resting pH 7.01±0.04 7.02±0.03  7.01±0.02 7.02±0.02  7.01±0.06 7.01±0.03 
 Exercise pH 7.00±0.05 6.96±0.10  7.00±0.04 6.97±0.07  7.00±0.06 6.95±0.13 
 Resting ADP, µM 8±5 8±6  8±6 7±4  8±5 10±8 
 Exercise ADP, µM 34±12 38±21  40±15 40±26  28±5 35±15  
 ADP t1/2, s 23±6 25±9  24±6 26±12  23±6 24±4 
 PCr t1/2, s 33±9 35±12  36±8 38±14  29±8 31±9 
Laboratory measurements         
 Ferritin, ng/mL 59(39-79) 34(18-50)  45(26-64) 33(18-48)  77(64-90) 44(28-60) 
 Transferrin saturation, % 18±10 21±8  12±5 16±7  24±10 25±6 
 Soluble transferrin receptor, mg/L 4.0±1.5 3.6±0.8  4.6±1.5 3.9±0.6  3.4±1.3 3.4±0.9 
 Hemoglobin, g/L 128±20 130±15  114±19 119±8  140±11 142±10 
 Creatinine, µmol/L 108±34 121±39  129±32 138±21  89±24 103±46 
 Aspartate transaminase, iU/L 22±9 22±8  25±8 21±7  20±10 24±8 
 C-reactive protein, mg/L 5(1-10) 6(3-9)  12(2-22) 5(3-8)  3(1-6) 6(1-11) 
 NT-proBNP, pg/mL 462(206-855) 1486(245-2054)  790(291-1944) 2696(423-3907)  316(133-629) 696(245-1900) 
Treatment         
 Diuretics, n (%) 12(63) 14(67)  8(89) 7(64)  4(40) 7(70) 
 ACE-inhibitor or ARB, n (%) 17(89) 16(76)  7(78) 9(82)  10(100) 7(70) 
 Beta-blockers, n (%) 16(84) 18(86)  7(78) 10(91)  9(90) 8(80) 
 Spironolactone, n (%) 12(63) 12(57)  5(56) 5(45)  7(70) 7(70) 
 Digoxin, n (%) 4(21) 6(29)  3(33) 2(18)  1(10) 4(40) 
 Anticoagulants, n (%) 3(16) 6(29)  1(11) 3(27)  2(20) 3(30) 
 Antiplatelets, n (%) 13(68) 13(62)  5(56) 8(73)  8(80) 5(50) 
Table 1. Baseline characteristics (continued). Data are mean±SD, numbers (%), or median (interquartile range). 
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Placebo 
(n=19) 
Iron Isomaltoside 
(n=21) 
Difference 
(95% CI) 
ANCOVA 
P-value 
Primary endpoint         
PCr t1/2, s 36±11 30±7 -6.8(-11.5,-2.1) 0.006 
Secondary endpoints     
ADP t1/2, s 24±9 20±6 -5.3(-9.7,-0.9) 0.02 
Hemoglobin, g/L 127±14 130±13 2.4(-3.5,8.4) 0.41 
Ferritin, ng/mL 57(41-84) 369(232-495) 304(217,391) <0.0001 
Transferrin saturation, % 21±9 29±6 6.8(2.7,10.8) 0.002 
NYHA class 2.6±0.5 2.3±0.5 -0.23(-0.46,-0.01) 0.04 
6 min walking distance, m 324±67 347±72 15(-10,40) 0.24 
Pre-exercise Borg dyspnea score 8±2 7±1 -0.6(-1.5,0.2) 0.12 
Post-exercise Borg dyspnea score 15±2 12±3 -2.0(-3.7,-0.3) 0.02 
Peak VO2/kg, mL/kg/min 14.9±3.5 16.8±4.7 0.5(-1.0,1.9) 0.54 
KCCQ overall score 55±24 68±17 12.7(-7.7,33.2) 0.18 
LV ejection fraction, % 39±8 41±7 2.2(-1.1,5.6) 0.19 
NT-proBNP, pg/mL 334(180-827) 1623(281-2453) 289(-461,1040) 0.44 
Resting PCr, mM 40±5 40±6 -0.2(-3.5,3.0) 0.89 
Exercise PCr, mM 26±6 25±6 -0.3(-3.6,3.0) 0.86 
Resting Pi, mM 3.8±1.1 4.0±1.0 0.3(-0.3,0.8) 0.33 
Exercise Pi, mM 18.2±7.2 17.6±6.7 -0.9(-5.0,3.2) 0.66 
Resting pH  7.01±0.3 7.01±0.3 -0.01(-0.02,0.01) 0.44 
Exercise pH 6.99±0.06 6.97±0.07 0(-0.04,0.04) 0.97 
Resting ADP, µM 7±5 8±5 0.9(-2.0,3.8) 0.52 
Exercise ADP, µM 34±15 37±18 1.2(-8.1,10.5) 0.80 
Safety endpoints     
Systolic blood pressure, mm Hg 119±14 127±12 7.1(-0.3,14.5) 0.06 
Diastolic blood pressure, mm Hg 72±13 74±10 0.7(-5.5,6.8) 0.83 
Heart rate, beats/min 74±12 71±10 -2.9(-8.8,3.1) 0.34 
Respiratory rate, breaths/min 16±1 15±1 -0.7(-1.2,-0.2) 0.009 
Creatinine, μmol/L 103±38 106±41 -3(-26,20) 0.80 
Aspartate transaminase, iU/L 22±6 30±26 8(-4,21) 0.21 
C-reactive protein, mg/L 4(2-8) 6(2-11) 0.4(-3.0,3.9) 0.79 
Table 2. Endpoints for total population 
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Placebo Iron Isomaltoside 
Difference 
(95% CI) 
ANCOVA 
P-value 
Anemic patients n=9 n=11   
PCr t1/2, s 38±12 30±9 -8.4(-16.7,-0.2) 0.04 
ADP t1/2, s 24±9 18±7 -6.3(-13.5,0.9) 0.08 
Hemoglobin, g/dL 117±12 124±6 5.5(-2.7,13.8) 0.18 
Ferritin, ng/mL 45±25 456±161 413(295,530) <0.0001 
NYHA class 2.7±0.5 2.5±0.5 -0.3(-0.6,0.1) 0.09 
Non-anemic patients n=10 n=10   
PCr t1/2, s 35±11 31±5 -5.2(-10.6,0.2) 0.06 
ADP t1/2, s 24±9 21±5 -4.4(-9.6,0.9) 0.10 
Hemoglobin, g/dL 135±9 137±15 0.5(-8.3,9.3) 0.72 
Ferritin, ng/mL 67±24 274±149 176(68,284) 0.003 
NYHA class 2.6±0.5 2.2±0.4 -0.2(-0.6,0.1) 0.23 
 
Table 3. Endpoints for anemic and non-anemic subgroups 
 
 
 
  
	
Fig. 1. Dynamic Quadriceps 31P Magnetic Resonance Spectroscopy (31P MRS). The figure shows the experimental setup and example data from multiple 
studies. Experiments are performed with subjects supine (A) and 31P coil and leg weight attached prior to entry into the magnet bore. 1H scout images of quadriceps 
are used to optimize positioning (B). 31P MRS data are shown as stacked plot of all phosphometabolite changes (C) and a timecourse of phosphocreatine signal (D) 
acquired during two bouts of exercise and recovery; PCr t1/2 is calculated from the recovery curve (interrupted line) shown in D. PDE = phosphodiester. 
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Fig. 2. FERRIC-HF II CONSORT Diagram. Patient disposition during the trial.
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Fig. 3. Primary Endpoint. Individual changes in PCr t1/2 with Iron Isomaltoside and saline placebo in total cohort. 
